(Total Views: 440)
Posted On: 03/25/2020 12:20:20 PM
Post# of 154115
Re: LaundryMoney #22992
“Look on the bright side, now NP and the board don't get the big set of options that were awarded based on getting the BTD.”
Honestly, I’d rather CYDY receive BTD and the board/NP receive the big set of options, but that outcome is up in the air as CYDY awaits the meeting with the FDA.
The meeting with the FDA is promising, as they’ll outline exactly what they require for the BTD, but what they request may take time. Do they want data from 10 patients? Do they want data that covers a 6 or 12 month period? I think only the FDA knows what they require and we (including CYDY) is just guessing.
NP should’ve set this meeting up back in January after the results from is MiL and patient #1 started to show promising outcomes. That way he could’ve got clear guide and won what the FDA wanted. Unfortunately, he got too excited and submitted the BTD a bit prematurely. Luckily the safety profile of leronlimab speaks for itself and CYDY has a history with the FDA.
Honestly, I’d rather CYDY receive BTD and the board/NP receive the big set of options, but that outcome is up in the air as CYDY awaits the meeting with the FDA.
The meeting with the FDA is promising, as they’ll outline exactly what they require for the BTD, but what they request may take time. Do they want data from 10 patients? Do they want data that covers a 6 or 12 month period? I think only the FDA knows what they require and we (including CYDY) is just guessing.
NP should’ve set this meeting up back in January after the results from is MiL and patient #1 started to show promising outcomes. That way he could’ve got clear guide and won what the FDA wanted. Unfortunately, he got too excited and submitted the BTD a bit prematurely. Luckily the safety profile of leronlimab speaks for itself and CYDY has a history with the FDA.
(4)
(0)
